Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Deal of the Week: Boston Scientific/Apama
Boston Scientific Corporation (NYSE: BSX) announced its second acquisition of the year, targeting privately held Apama Medical Inc. in a deal for $175 million. That’s small potatoes compared with its previously announced deal for Symetis SA, the Swiss maker of transcatheter aortic valve implantation devices, for $435 million. The Apama transaction consists of $175 million in cash up-front and a maximum of $125 million in contingent payments over the period of 2018-2020 based on achievements of clinical and regulatory milestones. Based in California, Apama Medical is developing radiofrequency balloon catheter system for the treatment of atrial fibrillation (AF). AF, a heart rhythm... Read More »
Deal of the Week: Shandong Weigao/Argon Medical Devices
In the first nine months of 2017, Chinese investment in U.S. healthcare companies rose 300% compared with all of 2016. Shandong Weigao Group (1066.HK), a Chinese developer of single-use medical devices, announced its acquisition of Texas-based Argon Medical Devices on September 24, marking the 12th acquisition by a Chinese company in 2017. Shandong agreed to pay $850 million for a 90% stake in the privately-held medical device maker. Argon develops, manufactures and sells devices for interventional radiology, vascular surgery, interventional cardiology, and critical care procedures, including biopsy products, drainage catheters and systems that remove blood clots. The company... Read More »Deal of the Week: Teleflex/NeoTract
The Deal of the Week (ended Sept. 8, 2017) is also the largest announced in the holiday-shortened work week. Teleflex Incorporated (NYSE: TFX) announced its first acquisition this year, paying $725 million upfront for privately held NeoTract, Inc. It marks a new focus for the medical device maker, whose previous buyouts concentrated in cardiovascular and microlaparoscopy surgical technologies. NeoTract is a medical device maker that has developed and commercialized the FDA-cleared UroLift System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. Anyone who watches professional sports televised on Sunday afternoons... Read More »
